 |
|
|
| |
The Combination of Grazoprevir (MK-5172), an NS3 Inhibitor, and MK-8408, an NS5A Inhibitor, Presents a High Genetic Barrier to Resistance in HCV Genotypes 1a and 3a
|
| |
| |
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Fred Lahser1, Karin Bystol1, Stephanie Curry1, Patricia McMonagle1, Rong Liu1, Ellen Xia2, Robert Chase1, Stuart Black1, Eric Ferrari1,Ling Tong3, Wensheng Yu3, Joseph Kozlowski3 and Ernest Asante-Appiah1
Departments of 1Infectious Diseases, 2In Vitro Pharmacology, 3Medicinal Chemistry, Merck & Co., Inc., Whitehouse Station, NJ, USA
|
| |
|
|
|
|
|
